Background and hypothesis: Mibefradil is the first compound of a new class of calcium
antagonists with a unique chemical structure and mechanism of action. This trial compared …

Mibefradil, a tetralol derivative, is a new long-acting calcium antagonist used for the
treatment of patients with hypertension and chronic stable angina pectoris. The drug is …

Mibefradil is a Ca2+ channel antagonist that inhibits both T-type and high-voltage-activated
Ca2+ channels. We previously showed that block of high-voltage-activated channels by …

1 The present study compared the cardiovascular effects of mibefradil (MIB), a novel Ca2+‐
channel antagonist with high selectivity for t‐type Ca2+‐channels to the effect of the l‐type …

Mibefradil is a single‐enantiomer calcium antagonist belonging to a new class, the tetralol
derivatives. The recommended doses for treatment of hypertension and chronic stable …

Pharmacotherapy with nitrates, β-blockers, and calcium antagonists is the cornerstone of
management of patients with chronic stable angina pectoris. While these agents are all …

Mibefradil is a tetralol derivative chemically distinct from other calcium channel antagonists.
It is a very effective antihypertensive agent that is thought to achieve its action via a higher …

Objectives. This study sought to assess the hemodynamic and cardiac effects of two dose
levels of mibefradil in patients with varying degrees of ischemic left ventricular dysfunction …

We compared detailed efficacy of efonidipine and nifedipine, dihydropyridine analogues,
and mibefradil using recombinant T-and L-type Ca2+ channels expressed separately in …

Basic studies as well as short-term clinical trials of the T-channel-selective calcium channel
blocker, mibefradil, are reviewed. The compound reduced afterload and was effective for the …